Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript

Novartis AG (NVS) Discusses REMODEL Trial Results for Remibrutinib in Relapsing Multiple Sclerosis Transcript

Seeking Alpha • a day ago

Novartis' breast cancer drug cuts risk of death by 19% after six years, data shows

Swiss drugmaker Novartis' drug Kisqali helped extend survival for women with ​a form of high-risk, early-stage breast cancer, ‌cutting their risk of death by 19% after six years, according to trial data presented at the European ​Society for Medical Oncology congress in Madrid ​on Friday.

Reuters • Oct 23, 2026

Novartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib

Swiss drugmaker Novartis' oral multiple sclerosis (MS) drug remibrutinib meaningfully reduced relapses in patients, according to data presented ​at a medical conference in Toronto on Friday, but less than ‌analysts had expected.

Reuters • Oct 23, 2026

Novartis Remibrutinib Cuts MS Relapses in Phase III, Eyes $4B Opportunity

Novartis NYSE: NVS presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton's tyrosine kinase inhibitor reduced relapse rates and MRI lesion activity versus teriflunomide in the REMODEL-1 and REMODEL-2 studies.

MarketBeat • Oct 24, 2026

Stay Ahead of the Game With Novartis (NVS) Q3 Earnings: Wall Street's Insights on Key Metrics

Evaluate the expected performance of Novartis (NVS) for the quarter ended September 2026, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.

Zacks Investment Research • Oct 22, 2026

Novartis: The Sell-Off Creates An Attractive Entry Point

On October 27, Novartis will report its results for the third quarter. As a reminder, its Q2 revenue rose 10.6% quarter-over-quarter to $14.95 billion, primarily due to the strong performance of the oncology portfolio and Cosentyx. On September 18, 2026, the EMA's CHMP adopted a positive opinion recommending approval of Cosentyx for patients suffering from polymyalgia rheumatica.

Seeking Alpha • Oct 19, 2026

Novartis ends mid-stage Fabhalta trial targeting serious kidney condition

Swiss drugmaker Novartis has terminated a mid-stage study testing its drug ​Fabhalta in patients with a ‌serious kidney condition, citing "strategic considerations", according to a federal clinical trials registry.

Reuters • Oct 16, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novartis AG - NVS

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Novartis AG ("Novartis" or the "Company") (NYSE: NVS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

PRNewsWire • Oct 15, 2026

NVS Wins FDA Nod for Label Expansion of Immunology Drug Rhapsido

Novartis wins FDA approval for Rhapsido in symptomatic dermographism, expanding its chronic hives opportunity as pipeline setbacks raise pressure for growth.

Zacks Investment Research • Oct 8, 2026

US FDA expands use of Novartis drug for chronic skin condition

The US Food and Drug Administration has expanded the use of Novartis' drug to treat adults with ​a chronic skin condition that causes recurring itchy welts, ‌the Swiss drugmaker said on Wednesday.

Reuters • Oct 7, 2026